Loading company…
Oxitope Pharma develops medicines for inflammatory and cardiovascular diseases linked to oxidative stress.
Oxitope Pharma develops antibodies targeting oxidized phospholipids for inflammatory and cardiovascular disorders. Its first development candidate focuses on acute indications, particularly cardiovascular disease. Based in the Netherlands, the company merged with Arxx Therapeutics AS in January 2024 to form Calluna Pharma.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in